Erapid
Research type
Research Study
Full title
Evaluating Treatment as Prevention among People Who Inject Drugs in Dundee for HCV (E-raPiD-HCV)
IRAS ID
234375
Contact name
John/F Dillon
Contact email
Sponsor organisation
University of Dundee
Duration of Study in the UK
5 years, 11 months, 30 days
Research summary
Hepatitis C virus (HCV) is a blood-borne virus that can seriously damage the liver and is spread mainly through blood-to-blood contact with an infected person. The greatest risk of acquiring the virus in the UK is through injecting drug use. Our modelling work shows that HCV treatment is a critical component to HCV prevention among people who inject drugs (PWID) and is likely to be cost-effective compared to delaying treatment or treating non-PWID with mild or moderate disease. The advent of new directly acting antiviral therapies, which are safer and more effective than previous treatments, makes treating hepatitis easier than before. The aim of this current study is to monitor the prevalence and incidence of Hepatitis C within Tayside as the level of treatment within the region is increased. Measures will be made at the population level on people who do not have HCV but have an indication for NHS testing for HCV, therefore no individual participants will be consented to the study.
REC name
East of Scotland Research Ethics Service REC 1
REC reference
17/ES/0136
Date of REC Opinion
27 Sep 2017
REC opinion
Favourable Opinion